Health
Ascentage Has First U.S. Biotech IPO of 2025, Raising $126M to Bring Its Cancer Meds to the World
Ascentage Pharma, a China-based drug developer with global ambitions, now has $126.4 million from a U.S. IPO that will mainly...
Why Sentara Health Invested $11M Into iPhones for Nurses
The country’s nursing shortage shows no signs of slowing — which means healthcare providers must remain committed to finding innovative,...
Astellas Exec Talks Dealmaking and Pipeline Strategy in Cancer, Gene Therapy & More
Cancer is well represented in the Astellas Pharma portfolio and pipeline, but the drugmaker has made diversification a key part...
All The Way With LBJ – A Half Century After His Passing
By MIKE MAGEE This is the 52nd anniversary of the death of Lyndon Baines Johnson from his 5th Heart Attack....
Cybersecurity Threats Continue to Rise for Healthcare Organizations, Research Shows
Cybercriminals remain a major threat in the healthcare sector — with the vast majority of healthcare organizations reporting spotting a...
Do We Need Humans in the Loop? A Novo Nordisk Exec Weighs In (Video)
Story follows beneath the quote from the extended video below “There’s very little need and this sounds cynical and I’m...
Maybe AI Doesn’t Read Blueprints
By KIM BELLARD Gosh, who knew that Jan 13 would be an AI day, with at least three major announcements...
AstraZeneca, Daiichi Sankyo ADC Lands FDA Approval in Advanced Breast Cancer
A targeted cancer therapy from AstraZeneca’s alliance with Daiichi Sankyo is now FDA approved to treat certain cases of advanced...
How Healthcare Leaders Reacted to the 15 Additional Drugs Selected for Medicare Negotiation Program
The U.S. Department of Health and Human Services unveiled 15 additional drugs chosen for the Medicare Drug Price Negotiation Program...
Transforming Our Collective Approach to Alzheimer’s Disease Care Begins with Early and Accurate Diagnosis
Over the last two years, we’ve seen some of the most impactful scientific advancements in Alzheimer’s disease diagnostics and treatment...